Impact of Low Flow Nocturnal Oxygen Therapy On Hospital Admissions and Mortality in Patients with Heart Failure and Central Sleep Apnea - DCC

低流量夜间氧疗对心力衰竭和中枢性睡眠呼吸暂停患者入院和死亡率的影响 - DCC

基本信息

  • 批准号:
    10005453
  • 负责人:
  • 金额:
    $ 105.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-01 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

Central sleep apnea (CSA), prevalent in approximately 40% of patients with heart failure with reduced ejection fraction (HFrEF), predicts high rates of morbidity, hospitalizations, and mortality. Adverse effects are thought to be attributable to hypoxemia, central nervous system arousal, and sympathetic nervous system activation resulting from episodic breathing disturbances and oxyhemoglobin desaturation. Until recently, the recommended treatment for CSA with HFrEF was adaptive servo-ventilation (ASV). A recent multi-national trial, however, identified an adverse effect of ASV on mortality, leaving a void in therapeutic options for patients with these co-morbid disorders. Although low flow nocturnal oxygen, which provides a physiologically sound intervention for blunting hypoxemia-associated physiological stresses and sympathetic activation, and improves short-term intermediate outcomes in patients with CSA and HFrEF, no large scale study yet has examined its long term impact on clinically important outcomes. We have assembled a team of leaders in cardiology, sleep medicine and clinical trials to conduct a pragmatic trial designed to test the hypothesis that nocturnal oxygen therapy (NOXT) in patients with CSA and HFrEF will reduce mortality and unplanned hospitalizations for worsening HF. Secondary endpoints evaluate other measures of morbidity and mortality, functional status, exercise capacity, quality of life, mood, and sleep quality. Using a double-blinded, randomized design, we will screen 2,450 patients with home sleep studies, estimating that 35% (n=858) will meet study eligibility criteria for CSA. Participants will be randomized to NOXT or sham-NOXT and undergo standardized assessments including a 6 minute walk test, complete validated questionnaires, and will be followed for study outcomes for as long as 4.5 years. Oxygen use and oxygen saturation levels will be centrally monitored using cloud-based software. Primary outcomes will be assessed using a time to first event analysis, and secondarily as recurrent event rates. Highly efficient methods for data capture and monitoring and project management will be deployed. Novel physiological markers of ventilation during sleep will be derived to identify responsive subgroups. This rigorous yet practical design will provide pivotal trial data needed to identify the role of a potentially beneficial and acceptable therapy which has yet to be tested on a large scale in a population with high morbidity and mortality, for a condition where there is no current evidence-based treatment. The sleep assessments and interventions are practically designed with the objective of facilitating their rapid uptake and use by the cardiology and sleep communities. This Data Coordinating Center application is to provide the study comprehensive, responsive, and innovative data management and study coordination services, biostatistical analysis, rigorous adjudication of study outcomes, and centralized sleep analysis and oxygen monitoring to ensure that the study meets its milestones.
中枢性睡眠呼吸暂停(CSA),在约40%的射血减少的心力衰竭患者中普遍存在 分数(HFrEF)预测高发病率,住院率和死亡率。不良影响被认为是 可归因于低氧血症、中枢神经系统唤醒和交感神经系统激活 由间歇性呼吸紊乱和氧合血红蛋白去饱和引起。直至最近缅甸国内 CSA伴HFrEF的推荐治疗是适应性伺服通气(ASV)。最近的一次多国审判, 然而,确定了ASV对死亡率的不利影响,为患有以下疾病的患者留下了治疗选择的空白 这些共病性疾病虽然低流量夜间氧气,这提供了一个生理健全的 用于减弱低氧血症相关的生理应激和交感神经激活的干预,并改善 CSA和HFrEF患者的短期中期结局,尚未有大规模研究对其进行评估。 对临床重要结局的长期影响。我们召集了一个心脏病学,睡眠, 医学和临床试验,进行一项务实的试验,旨在测试的假设,夜间氧气 CSA和HFrEF患者的NOXT治疗将降低死亡率和计划外住院, HF恶化。次要终点评价了发病率和死亡率、功能状态, 运动能力、生活质量、情绪和睡眠质量。采用双盲随机设计,我们将 通过家庭睡眠研究筛选2,450例患者,估计35%(n = 858)将符合以下研究合格标准: CSA。受试者将被随机分配至NOXT组或假NOXT组,并接受标准化评估,包括 6分钟步行测试,完成经验证的问卷,并将随访研究结果, 4.5年氧气使用和氧饱和度水平将使用基于云的软件进行集中监测。 将使用至首次事件时间分析评估主要结局,其次评估复发事件率。 将采用高效的数据采集和监测及项目管理方法。小说 将导出睡眠期间通气的生理标记以识别响应亚组。这种严格 然而,实际的设计将提供关键的试验数据,需要确定的作用, 可接受的治疗方法尚未在发病率高的人群中进行大规模测试, 死亡率,对于目前没有循证治疗的情况。睡眠评估和 干预措施的实际设计目标是促进心脏病学的快速吸收和使用 睡眠社区此数据协调中心应用程序将提供全面的研究, 响应迅速,创新的数据管理和研究协调服务,生物统计分析,严格的 研究结果的裁定,以及集中睡眠分析和氧气监测,以确保研究 达到它的里程碑。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Susan S. Redline其他文献

Systemic <em>Malassezia furfur</em> infections in patients receiving intralipid therapy
  • DOI:
    10.1016/s0046-8177(85)80253-7
  • 发表时间:
    1985-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Raymond W. Redline;Susan S. Redline;Bernard Boxerbaum;Beverly Barrett Dahms
  • 通讯作者:
    Beverly Barrett Dahms

Susan S. Redline的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Susan S. Redline', 18)}}的其他基金

Impact of Low Flow Nocturnal Oxygen Therapy On Hospital Admissions and Mortality in Patients with Heart Failure and Central Sleep Apnea - DCC
低流量夜间氧疗对心力衰竭和中枢性睡眠呼吸暂停患者入院和死亡率的影响 - DCC
  • 批准号:
    9751958
  • 财政年份:
    2018
  • 资助金额:
    $ 105.59万
  • 项目类别:
Phenotypic and Molecular Signatures for Sleep Apnea and Related Morbidities
睡眠呼吸暂停及相关疾病的表型和分子特征
  • 批准号:
    10544494
  • 财政年份:
    2017
  • 资助金额:
    $ 105.59万
  • 项目类别:
Phenotypic and Molecular Signatures for Sleep Apnea and Related Morbidities
睡眠呼吸暂停及相关疾病的表型和分子特征
  • 批准号:
    9244394
  • 财政年份:
    2017
  • 资助金额:
    $ 105.59万
  • 项目类别:
Phenotypic and Molecular Signatures for Sleep Apnea and Related Morbidities
睡眠呼吸暂停及相关疾病的表型和分子特征
  • 批准号:
    10321951
  • 财政年份:
    2017
  • 资助金额:
    $ 105.59万
  • 项目类别:
Impact of treatment of mild sleep-disordered breathing on children's health-DCC
治疗轻度睡眠呼吸障碍对儿童健康的影响-DCC
  • 批准号:
    9325560
  • 财政年份:
    2015
  • 资助金额:
    $ 105.59万
  • 项目类别:
National Sleep Research Resource (NSRR)
国家睡眠研究资源 (NSRR)
  • 批准号:
    8476057
  • 财政年份:
    2013
  • 资助金额:
    $ 105.59万
  • 项目类别:
National Sleep Research Resource (NSRR)
国家睡眠研究资源 (NSRR)
  • 批准号:
    9303430
  • 财政年份:
    2013
  • 资助金额:
    $ 105.59万
  • 项目类别:
National Sleep Research Resource (NSRR)
国家睡眠研究资源 (NSRR)
  • 批准号:
    8730710
  • 财政年份:
    2013
  • 资助金额:
    $ 105.59万
  • 项目类别:
Sleep-Disordered Breathing and Risk for CVD and Stroke in the Jackson Heart Study
杰克逊心脏研究中睡眠呼吸障碍与心血管疾病和中风的风险
  • 批准号:
    8473916
  • 财政年份:
    2012
  • 资助金额:
    $ 105.59万
  • 项目类别:
Sleep-Disordered Breathing and Risk for CVD and Stroke in the Jackson Heart Study
杰克逊心脏研究中睡眠呼吸障碍与心血管疾病和中风的风险
  • 批准号:
    8297074
  • 财政年份:
    2012
  • 资助金额:
    $ 105.59万
  • 项目类别:

相似海外基金

I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
    Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
    Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
    Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 105.59万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了